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Abstract 
Introduction: While several studies have shown an association of QEEG band power with 
negative symptoms in patients with schizophrenia, this has not yet been investigated in a 
sample with neuroleptic-naïve first-episode patients (NNFE) up to now. From literature we 
hypothesized delta (0.5–4 Hz) and theta (4–8 Hz) power to be augmented and alpha (8–12 
Hz) power to be decreased with increased negative symptoms in NNFE. 
 
Materials and methods: The sample consisted of 27 NNFE. Psychopathology was rated with 
the Scale for the Assessment of Negative Symptoms (SANS). EEG was recorded from 21 
electrodes according to the 10/20 system. Spectral analysis was performed on mean power of 
8 electrodes in seven frequency bands after artefact removal. Linear regressions were 
calculated with log transformed power as dependent and psychopathology as independent 
variable. We controlled for medication, drugs, age, sex, education and day time of EEG 
recording. 
 
Results: A positive correlation of SANS global scorewith power in delta and theta frequency 
bands could be confirmed in NNFE. In the alpha1 (8–10 Hz) band we found no significant 
correlation with negative symptoms and in the alpha2 (10–12 Hz) band therewas a positive 
correlation with SANS (p=0.069). Beta1 (12–15 Hz) power also correlated positively with 
SANS.  
 
Discussion: The present results confirm the correlation of negative symptoms with power of 
slow frequency bands. In addition to previous studies in chronic schizophrenia patients, the 
effect was shown in NNFE, which is compatible with augmented slow wave power being a 
marker for negative symptoms in psychosis. 
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1 Introduction 
 
QEEG slow wave excess (delta and theta) is considered a robust organic sign of schizophrenia  
and has been found in medicated as well as in unmedicated patients (John et al., 1994; 
Boutros et al., 2008).  Most studies also found a decrease in alpha power (Boutros et al., 
2008) and reported a predominantly frontal localization of these effects (Wuebben and 
Winterer, 2001; Mientus et al., 2002).   
As schizophrenic syndromes are clinically heterogeneous, the abnormalities might result from 
different etiologies. One major aspect within the phenomenological entity of “schizophrenia” 
is the occurrence of negative symptoms. Therefore, it is of interest to investigate the 
association negative symptoms with EEG spectral power variations as a physiological marker 
for this clinically observed phenomenon. Negative symptoms are consistently associated with 
increased slow wave activity (Gattaz et al., 1992; Gerez and Tello, 1995; Gerez and Tello, 
1995; Harris et al., 1999; Winterer et al., 2000; Sponheim et al., 2000). The results for the 
alpha band are rather inconsistent: decreased alpha activity (Sponheim et al., 2000; Merrin 
and Floyd, 1996) as well as augmented alpha activity (Gerez and Tello, 1995) has been found 
in association with negative symptoms.  Finally Harris et al., (1999) found increased beta 
band activity in relation to negative symptoms. For an overview, see Table 1.  
 
Insert Table1 
 
While slow wave excess in patients with stronger negative symptoms seems to be a stable 
result, other findings such as power alteration in the alpha band differ between studies. These 
differences in results might depend on the current illness state rather than the diagnosis itself, 
or even on medication or alertness.  
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 This study aims to confirm the presence of slow wave augmentation in patients with negative 
symptoms in NNFE. This would underline this finding as being independent of neuroleptic 
medication on one hand. On the other hand it would be in favour of the hypothesis that the 
slow wave phenomenon has characteristics of a trait marker because it is already present in a 
very early stage of the disease.  
Concerning the alpha and beta frequency ranges most studies found an alpha decrease. 
Therefore, our second hypothesis was an alpha decrease with augmented negative symptom 
score. 
 
2 Materials and methods 
 
2.1 Subjects  
 
We recruited patients with a first episode of psychosis from the early Basel “Prediction and 
early detection of psychosis - a prospective multilevel approach" study, which aims to improve the 
early detection of psychosis. The multi-domain assessment approach used in this study covers 
psychopathological, neuropsychological, neurophysiological, and neuroimaging 
investigations. The study design and preliminary results of the study have been described in 
detail elsewhere (Riecher-Rossler et al., 2007). 
Patients with suspected psychosis were referred from general practitioners, psychiatrists in 
private practice, and from the Psychiatric Outpatient Department of the University Hospital of 
Basel.  Inclusion criteria were defined according to Yung et al. (1998) based on the Brief 
Psychiatric Rating Scale (BPRS). Patients with previously diagnosed schizophrenia, 
substance-induced psychosis, age below 18 years, inadequate knowledge of the german 
language, and intelligence below IQ of 70 were excluded. 
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 We analyzed data of 27 (11 women and 16 men) neuroleptic-naïve first episode (FE) 
patients. Mean age was 32 (± 8.9 SD) years. The actual medication of the participants were: 
antidepressants (2 citalopram and 1 paroxetin) and benzodizepines (3 lorazepam, 1 
oxazepam). The benzodiazepines were prescribed for sedation. 8 patients used cannabis. The 
ICD-10 diagnoses of our patients were as follows: 16 patients with “paranoid schizophrenia”, 
7 patients with “acute polymorphic psychotic disorder with symptoms of schizophrenia”, 3 
patients with “undifferentiated schizophrenia”, and 1 patient with “hebephrenic 
schizophrenia”. After complete description of the study to the subjects, written informed 
consent was obtained from all participants. The study was approved by the local ethics 
committee (Ethikkommission beider Basel, EKBB). 
 
2.2 Psychopathological Ratings 
 
Patients were rated with the Scale for the Assessment of Negative Symptoms (SANS) 
(Andreasen, 1989) which consists of five subscales that evaluate aspects of negative 
symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality, and attentional 
impairment. We calculated SANS global score by counting one point for every existent item. 
The mean SANS global score was 7.4 (standard deviation: 4.6, median: 8, minimum:0, 
maximum:18) and the variable was normally distributed.  
 
2.3 EEG - Data Acquisition 
 
Routine EEG recordings were performed in a quiet room with patient either sitting or lying in 
supine position with eyes closed; the recordings lasted about 20 minutes and included several 
episodes with opening and closing of eyes. 
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 EEG data were digitally recorded with 21 gold cup electrodes placed according to the 
international 10/20 system.  Impedances were kept below 5 kΩ. Amplifiers were calibrated 
using a 50 µV square pulse. Sampling frequency was 250 Hz with high- and low pass filters 
set to 0.5-120 Hz. All channels were referenced to linked ears.  EEGs were recorded with 
Alliance Works for Windows NTTM. 
Raw EEG data were converted to European Data Format with Nicolet Data Converter. 
The converted data were then read into Brain Vision Analyzer software (© Brain Products 
GmbH, Munich, Germany; BVA). With BVA we selected 19 electrodes (Fp1, Fp2, F3, F4, 
C3, C4, P3, P4, O1, O2, F7, F8, T3, T4, T5, T6, Fz, Cz and Pz), recalculated the reference to 
average and set the high- and low pass (Butterworth) filters to 0.5 – 120 Hz. We then 
removed eyes open sequences that had been marked by the laboratory assistants during the 
recording with the tool “Segmentation” of  BVA.  
 
2.4 Artefact Rejection 
 
To ensure a high validity of the analysis Boutros et al. (Boutros et al., 2008) recommend a 
minimum of 25 artefact free segments of 2 seconds duration. To conserve a maximum of EEG 
recording we developed a semi-automatic standard operating procedure (SOP) to remove 
artefacts. The procedure can be explained in three steps.  
1. Visual inspection of the EEG recording was performed, obvious artefacts (e.g. electrode 
artefacts), except for those caused by eye movements, were manually removed with the tool 
“Raw Data Inspector” of BVA. 
2. In order to remove well defined sources of artefact, an ICA (Independent Component 
Analysis) was performed with BVA. Once the independent time courses of different brain and 
artefact sources are extracted from the data, corrected EEG signals can be derived by 
eliminating the contributions of the artefactual sources. The ICA has been demonstrated to 
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 reliably isolate artefacts due to horizontal and vertical eye movements, heart and to certain 
extent muscle or line noise (Jung et al., 2000). 
3. In a last step the already corrected EEG was visually inspected by an experienced 
neurophysiologist who was blind to the patient’s symptoms. He cut further artefacts not 
readily removed in steps 1 and 2 from the EEG recording: muscle, movement and electrode 
artefacts; patients with EEGs containing deeper sleep than stage A of Loomis et al. (1937) and 
with EEGs that showed EEG-identifiable pathologies (e.g. generalized epilepsy) were 
excluded. 
After artefact-removal, EEG was divided in segments of two seconds. The remaining EEG 
recordings had a minimum length of 69 two-second-segments (over 2 minutes), an average of 
172 (over 5 minutes) and a standard deviation of 45 segments.   
 
2.5 Analysis and Statistics 
 
Power was calculated with Fast Fourier Transformation (Hanning Window, 10% taper length) 
using Brain Vision Analyzer Software for 0.5 Hz bins from 0.5 Hz up to 30 Hz over 19 
electrodes and then exported into R-Software (R Development Core Team, 2007) for 
statistical analysis.  
The FFT output data over the 0.5 Hz bins were combined to delta (0.5-4 Hz), theta (4-8 Hz), 
alpha1 (8-10 Hz), alpha2 (10-12 Hz), beta1 (12-15 Hz), beta2 (15-25 Hz) and beta3 (25-30 
Hz) bands. Analyses were performed on average power of the  8 electrodes used in the study 
of Gross et al. (1996) over the anterior half of the scalp (Fp1, F3, C3, Fz, Cz, Fp2, F4, C4) 
(other locations were not tested to keep the number of variables small). EEG variables were 
then log transformed to achieve normal distribution.  
In a first step of data analysis we controlled for the following confounding factors: age, 
gender, education, day time of recording, use of tranquilizers, antidepressants, and cannabis 
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 by calculating correlations of these confounders with the power in every band. Confounding 
factors that were significant at a conservative level of p < 0.1 were taken into account in the 
next step. 
We then performed one linear regression analysis for every band. Power was used as 
dependent variable. The psychopathological ratings were taken as independent variables, and 
we controlled for the effect of the previously selected confounding factors by including them 
as further independent variables into the regression model of the band in which they were 
relevant. We then dropped non relevant explaining variables from the models using a stepwise 
backwards elimination procedure based on Akaike's information criterion (AIC) as it is 
implemented in the R software for statistical computing. However, in case the negative 
symptom variable was dropped by this automatic procedure we decided to leave it within the 
model because it is in the focus of interest of the actual study.   
 
3  Results 
 
The confounder analysis of step one revealed that day time of EEG recording is a relevant 
confounder in the delta (r = 0.34, p = 0.083), theta (r = 0.34, p = 0.085) and the alpha1 (r = 
0.33, p = 0.096) bands. Only this variable was initially included in the regression models.  
The regression analysis showed a significant effect of negative symptoms in the delta (p = 
0.011), theta (p = 0.026) and beta1 (p = 0.009) and a trend (p = 0.069) in alpha2 bands. In 
these frequency-bands power increases in correlation with stronger negative symptoms. For 
details of regression models see Table2. 
 
Insert Table 2 
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 To facilitate comparison with results from other studies, we plotted the correlation 
(Spearman) of power in 0.5 Hz frequency bins with SANS global score instead of using 
predefined bands (Figure I).   
 
 Insert Figure 1  
 
3.1 Additional confounding factor analysis 
 
We had to initially preselect confounding factors to include in the statistical analysis to keep 
the number of variables small. However there is a danger that the confounding factors that did 
not correlate with power –as tested previously- could still have an effect of the results. 
Therefore we performed post hoc sensitivity analysis of the confounding factors including 
them one by one into the regression models: All additionally included confounding factors 
(including medication, age, gender, education and cannabis use) were dropped by a stepwise 
backwards elimination process and had no effect on the results of the paper.   
Still, intake of benzodiazepines was especially problematic, since it was significantly  related 
with the negative symptom score (t-test, p-value = 0.017). To additionally rule out the effect 
of benzodiazepine, we recalculated the effect of negative symptoms by excluding the 4 
patients on benzodiazepines: We observed the same significant effects (in the delta, theta and 
beta1 bands) and also a trend in the alpha2 band in this reduced and more homogeneous 
sample (N = 23). 
We applied the same methods for the patients with cannabis use: The correlation of cannabis 
use with the negative symptom scoring was close to zero (r = 0.07, p-value = 0.719). 
Excluding patients using cannabis on a regular basis (N = 20 patients left) we still found the 
same effects whereas the previously significant result in the theta band became a trend (p = 
0.058) and the effect in alpha2 became significant (p = 0.04). 
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4 Discussion 
 
This study shows increased power in the EEG frequency ranges from 0.5-8 Hz and from 10.5-
15 Hz in correlation with negative symptoms in neuroleptic-naïve patients with a first episode 
of psychosis. 
 Several factors could potentially affect this result: The level of alertness influences the EEG 
frequency pattern but was controlled in this study by repeatedly opening and closing the eyes. 
Moreover, we tried to control for this effect by excluding EEG recordings with signs of sleep 
deeper than stage A of Loomis (1937) and by controlling for the time of day of the recording. 
Power in delta, theta and alpha1 correlates positively with progressing time of day of the EEG 
recording. This phenomenon is probably an expression of changes due to the circadian rhythm 
(Cajochen and Dijk, 2003). When adding this factor into the regression analysis the effect of 
negative symptoms was revealed to be more pronounced.  
Another potential problem of this study is related to the muscle activity recorded by the EEG: 
As we wanted to conserve a maximum of segments, it was not always possible to remove 
muscle noise to 100 %. Due to this, one limitation of this study could be the effect of the 
remaining muscle artefacts. Surface EMG activity goes down as far as 12-15 Hz and overlaps 
with beta band (Gotman et al., 1975; O'Donnell et al., 1974). Goncharova et al. (2003) 
demonstrated that frontalis and temporalis muscle had maximum amplitude frontally from 20 
to 30 Hz and temporally from 40 to 89 Hz. This means that delta, theta and alpha band results 
remain largely unaffected but there might be a chance for beta band results to be slightly 
influenced by muscle artefacts.  
A further difficulty is of course the use of medication and cannabis, as psychoactive 
compounds affect the electrical brain activity in many ways (Wauquier, 2005). The results of 
this study were probably, even if slightly, contaminated by the use of different substances. 
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 Since no chemical tests were performed simultaneously with EEG recordings, controlling 
statistically based on clinical data is the best available approximation to homogenous 
experimental setting. Therefore, one major limitation of this study was the use of 
benzodiazepines. Benzodiazepines are known to induce changes in the beta activity. The 
frequency and amplitude of these changes depend on various factors like age, type of 
medication and environmental conditions (Wauquier, 2005). The same accounts for the use of 
cannabis that has been shown to induce an alpha augmentation (Struve et al., 1999).  
However, with the additional post hoc exclusion of patients using benzodiazepines or 
cannabis described in the results section we assume that the observed changes in the power of 
theta and delta frequencies in relation to negative symptoms are not due to effects of 
benzodiazepines nor cannabis.  
One of the strong aspects of this study is that we can rule out the effect of neuroleptic 
medication as all our patients were neuroleptic naive. Earlier studies with medication-free 
patients applied withdrawal periods between 24 hours and 2 weeks. Neuroleptics are known 
to influence EEG frequencies and their effects differ between substances (Wauquier, 2005). 
Additionally, little is known about the long term effects of neuroleptics on EEG frequencies 
(Wauquier, 2005), and therefore, having patients medication-free for a limited time period 
adapted to the pharmacokinetic properties of the substance may not be sufficient to control for 
all their effects.  
Keeping these limitations and advantages of our study in mind, our first hypothesis derived 
from literature is supported: low frequency band power is linked with negative symptoms in 
neuroleptic-naïve schizophrenic patients with a first psychotic episode. For delta (0.5-4 Hz) 
our results are comparable to the studies of Gattaz et al. (1992), Harris et al. (1999),   
Sponheim et al. (2000), Winterer et al. (2000) and Gross et al. (2006); for theta (4-8 Hz) they 
are in line with the studies of Gerez and Tello (1995), Sponheim et al. (2000) and partly with 
Winterer et al. (2000).  
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 Many studies (Boutros et al., 2008) reported group differences of healthy controls compared 
to schizophrenic patients in slow wave activity (δ and θ). The results of the present study and 
others (Gattaz et al., 1992; Gerez and Tello, 1995; Harris et al., 1999; Sponheim et al., 2000; 
John et al., 2007; Gross et al., 2006) point to the hypothesis that these group differences are 
mainly explainable by negative symptoms in schizophrenic patients. Correlation of slow wave 
activity with negative symptoms has consistently been found in schizophrenic patients while  
correlations with positive symptoms are a inconsistent result in literature (e.g. Omori et al. 
(1995) vs. Merrin et Floyd (1996) ). 
The second hypothesis derived from literature linking a decrease of alpha power with 
negative symptoms is not confirmed.  Instead, we found positive correlations with negative 
symptoms, the opposite effects of our hypothesis, in the alpha2 (10-12 Hz, p = 0.069) and 
beta1 (12-15 Hz) bands in these patients in a very early stage of schizophrenia. While this is 
in contradiction to the studies of Merrin and Floyd (1996) and Sponheim et al. (2000), our 
results are similar to Gerez and Tello (1995) who found an alpha (7.5 -12.5 Hz) augmentation 
in patients in remission 2 years after a first episode of schizophrenia.  
If we are allowed to speculate on the psychophysiological mechanisms we propose that both 
negative symptoms and altered cortical rhythms represent dysregulation of prefrontal and 
limbic circuits linking the basal ganglia, thalamus and cerebral cortex. Interestingly, altered 
cortical rhythms have observed also in dementia of parkinsons’ disease which begins as a 
dysexecutive syndrome with some similarities to negative symptoms of schizophrenia, and 
which most likely results from malfunction of these circuits (Van Cott and Brenner (2005)). 
To the best of our knowledge this is the first study on this topic with a pure sample of 
neuroleptic naïve first episode patients. The paper states that there is a correlation between 
negative symptoms and EEG power in delta, theta and beta1 frequency bands at a very early 
stage of the disease. While this correlation is found in the group, it is not possible to decide 
ultimately whether the observed phenomenon is a marker of state changing with symptom 
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 strength in the individual or a diagnostic marker of the disease (“trait marker”). A clear 
differentiation between these two possibilities can be drawn only from repeated measures 
obtained from the same individuals at times of relative health and at times of increased 
symptoms. This would be a very interesting issue to address in the future. 
Another interesting question is whether the observed phenonomenon is also present in the 
prodromal phase of the disease. In a next step, we will therefore investigate this question in 
individuals in an at-risk mental state for psychosis. In these individuals EEG might contribute 
to the identification of those, who are in the prodromal phase of schizophrenia with purely 
negative symptoms (Riecher-Rossler et al., 2007).   
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